Flagship Pioneering and Lean Business Services Company Announce Collaboration to Advance Healthcare Innovation and AI-Enabled Biomedical Research in Saudi Arabia

Flagship Pioneering and Lean Business Services Company announced a strategic collaboration to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia after signing a Memorandum of Understanding at the BIO International Convention in San Diego on June 23, 2026. The partnership pairs Lean's national digital health platforms and health transformation capabilities with Flagship's life sciences, artificial intelligence and venture-creation expertise to accelerate precision medicine, scientific discovery and the development of a life sciences ecosystem aligned with Saudi Vision 2030.

“We are in a new era in which AI and health data are fundamentally reshaping how we understand disease, discover medicines, and improve patient outcomes,” said Junaid Bajwa, M.D., Senior Partner, Flagship Pioneering. “Flagship has been at the forefront of applying AI across scientific research, platform innovation, and company creation, and we believe the combination of Lean's exceptional data infrastructure and Saudi Arabia's ambitious vision creates a uniquely powerful opportunity. Together, we can build an innovation ecosystem that accelerates discovery and delivers meaningful impact for patients in the Kingdom of Saudi Arabia and globally.”

Context and scope of the collaboration

The Memorandum of Understanding establishes a framework for joint work that will explore the responsible application of artificial intelligence, advanced analytics and digital health capabilities across scientific research and healthcare innovation. Any future project-specific activities will be subject to approvals, privacy safeguards, regulatory requirements and agreed governance frameworks in accordance with Saudi law.

• Partners: Flagship Pioneering — the scientific innovation company behind Moderna, Generate Biomedicines and more than 100 other life sciences ventures — and Lean Business Services Company, a Public Investment Fund company and the Kingdom's national leader in digital health transformation.
• Flagship profile: Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures and was operating with $14 billion of assets under its direction as of its latest capital raise announced in July 2024. Its ecosystem includes companies such as Foghorn Therapeutics, Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Moderna, Sana Biotechnology, Tessera Therapeutics and Valo Health.
• Lean profile: Lean provides national health platforms, interoperability infrastructure, advanced analytics and AI-powered solutions intended to enable healthcare stakeholders across the Kingdom to accelerate innovation and improve patient outcomes.
• First 12 months: The collaboration will focus on evaluating priority initiatives, establishing foundational governance models and identifying opportunities to strengthen Saudi Arabia's life sciences ecosystem.

“Data and artificial intelligence are transforming how we understand disease, accelerate discovery, and improve patient outcomes. Saudi Arabia is uniquely positioned to lead this transformation through its investments in digital health, AI, and healthcare innovation,” said Eng. Mohanned Alrasheed, Chief Executive Officer of Lean Business Services. “As the Kingdom's national leader in health transformation, Lean is committed to enabling innovation that improves health outcomes and advances scientific progress. Together with Flagship Pioneering, we aim to strengthen Saudi Arabia's life sciences ecosystem and support the Kingdom's ambition to become a global leader in health innovation under Vision 2030.”

Outlook

The agreement signals an intent to marry national health data capabilities with private-sector life sciences platforms and AI expertise to catalyse discovery and commercialisation in the Kingdom. If realised, initiatives emerging from the collaboration could accelerate precision medicine programmes, bolster local research and development capacity, and attract further global partnerships — all while operating under privacy, security and regulatory safeguards pledged by both organisations.